August 6, 2025Scholar Rock Holding Corporation misses on earnings expectations. Reported EPS is $-0.98 EPS, expectations were $-0.66. Operator: Good morning, ladies and gentlemen, and welcome to the ...

Scholar Rock Holding SRRK -4.80% + Free Alerts has outperformed the market over the past 5 years by 7.22% on an annualized basis producing an average annual return of 21.06%. Currently, Scholar Rock ...

Q2 2025 Management View CEO David L. Hallal emphasized Scholar Rock is “scaling for the next phase of growth as a commercial stage fully integrated global biopharmaceutical company.” He outlined three ...

It didn't take a high-powered academic to figure out why Scholar Rock 's (NASDAQ: SRRK) share price swooned by more than 5% ...

No revenue was recorded as the company remains pre-commercial, in line with analyst expectations. R&D and G&A expenses surged 47% and 191% year over year as apitegromab advanced toward anticipated U.S ...

Anyone who’s attended college knows juggling a hefty schedule and making time for a social life can be hard, but one UA ...

Fifty years ago, the Boss was at a pivotal moment in his career. A new book details what it took to launch 'Born to Run' ...

Scholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025 Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical ...

Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial ...

Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the ...

Although there are many examples throughout history of positive changes in top company management teams, important personnel moves tend to unsettle investors. Scholar Rock's C-suite now looks ...

Biotech stock Scholar Rock (SRRK -1.28%) was popular among investors on Wednesday after a positive new analyst note on the company made the rounds.